vTv Therapeutics Screens First Patient In CATT1 Pivotal Trial Evaluating Cadisegliatin For Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics has screened the first patient in its CATT1 pivotal trial for Cadisegliatin, a potential first-in-class oral liver selective glucokinase activator for Type 1 Diabetes (T1D). The drug has been granted Breakthrough Therapy designation by the FDA and has been dosed in over 500 subjects, including 300 patients with diabetes.

June 24, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
vTv Therapeutics has initiated the CATT1 pivotal trial for Cadisegliatin, a potential first-in-class treatment for Type 1 Diabetes, which has FDA Breakthrough Therapy designation.
The initiation of the CATT1 pivotal trial for Cadisegliatin, a drug with FDA Breakthrough Therapy designation, is a significant milestone for vTv Therapeutics. This could lead to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100